EPIX Pharmaceuticals Announces Formation of Technology Advisory Board.
LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced the formation of a Technology Advisory Board (TAB) that includes several leaders in the field of computational technologies. The EPIX TAB has been established to advise the company on key aspects of its computational technologies including EPIX's proprietary in silico modeling for drug discovery. The charter members of the TAB, convening its inaugural session this week, include Charles L. Brooks, III, Ph.D., Johan Aqvist, Ph.D., and Gabriele Cruciani, Ph.D.
"We are pleased to announce the formation of the EPIX Technology Advisory Board and welcome the additional experience and knowledge of these accomplished thought-leaders, which should be additive to our current and future in silico discovery and development efforts," said Hanoch Senderowitz, executive director of Computational Development. "We believe the TAB is a vital strategic asset for our continued growth, and we look forward to collaborating with the members of our TAB as we continue to pursue new discovery targets, develop our lead therapeutic product candidates and expand our proprietary technology footprint."
About the EPIX TAB
Charles L. Brooks, III, Ph.D.
Professor Brooks is the Warner-Lambert/Parke-Davis professor of chemistry and a professor of biophysics in the Department of Chemistry at the University of Michigan.
Professor Brooks' research interests focus on the application of statistical mechanics, quantum chemistry and computational methods to chemically- and physically-oriented problems in biology. His current research interests include: free energy based methods for screening and optimization lambda-dynamics; ligand docking, protein stability and continuum based free energy approximations; the development of new polarizable force fields for proteins, lipids and small molecules; protein folding; and, protein structure prediction, ab initio folding, homology modeling. Professor Brooks is the author/co-author of more than 240 journal articles and book chapters.
Johan Aqvist, Ph.D.
Professor Aqvist is a professor of theoretical chemistry in the Department of Cell and Molecular Biology at Uppsala University, Sweden. Research in his group is focused on protein structure and function with a particular emphasis on enzymatic catalysts and binding energies between proteins and their ligands.
Professor Aqvist is the developer of the Linear Interaction Energy (LIE) method which he has successfully applied to the prediction of binding free energies in a variety of systems. Dr. Aqvist also is conducting work on the hERG channel; a large scale hERG binding prediction project is currently ongoing in his lab. Professor Aqvist is the author/co-author of more than 130 journal articles and book chapters.
Gabriele Cruciani, Ph.D.
Professor Cruciani is a professor of organic chemistry and cheminformatics in the Laboratory for Chemometrics and Cheminformatics at the University of Perugia, Italy. In addition, he serves as the scientific director of Molecular Discovery Ltd., a scientific software company focused on the development of computational tools based on the GRID force field with an emphasis on ADMET predictions.
Professor Cruciani's expertise includes ADMET predictions with a particular emphasis on hERG and CYPs. Professor Cruciani is the author/co-author of more than 100 journal articles and book chapters.
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics and Bayer Schering Pharma. For more information, please visit the company's website at www.epixpharma.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 14, 2008|
|Previous Article:||76 percent of U.S. CEOs see greater inbound foreign investment in the next year.|
|Next Article:||NPD Looks at Back-to-School 2008 in Challenging Times.|